Informations générales (source: ClinicalTrials.gov)

NCT04250493 En recrutement
Insulin Resistance in Multiple System Atrophy
Interventional
  • Atrophie
  • Insulinorésistance
  • Syndrome de Shy-Drager
  • Atrophie multisystématisée
N/A
University Hospital, Bordeaux (Voir sur ClinicalTrials)
octobre 2020
octobre 2027
16 septembre 2025
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder. The pathologic hallmark is the accumulation of aggregated alpha-synuclein in oligodendrocytes forming glial cytoplasmic inclusions. Some symptomatic treatments are available while disease-modification remains an unmet treatment need. Post-mortem findings suggest insulin resistance, i.e. reduced insulin signaling, in the brains of MSA patients. The aim of this study is to complete the target validation of insulin resistance for future treatment trials.
 Voir le détail

Etablissements

Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CHU de Bordeaux - 33 076 - Bordeaux - France Wassilios MEISSNER En recrutement Contact (sur clinicalTrials)

Critères

Tous
Inclusion Criteria:

Patients :

- Patients suffering from "possible" or "probable" MSA according to clinical consensus
criteria (Gilman et al., 2008).

- Age > 30

- Written informed consent

- Patient covered by the national health system

Controls:

- Patients not suffering from a neurologic disorder

- Age > 30

- Written informed consent

- Patient covered by the national health system


For patients and controls:

- Presence of a diabetes

- Treatment with corticosteroids, estrogen, atypical antipsychotics, and
anti-retroviral agents

- Patient under tutelage

- Patient unable to give consent

- Any other neurologic disorder

- Pregnancy and breastfeeding

- MOCA ≤21

- Contraindication to perform an MRI